CRISPR Technology Market by Product, Services, Application, End User

List of Tables

The CRISPR Technology Market is projected to reach USD 9.49 billion by 2030 from USD 2.80 billion in 2022, at a CAGR of 16.44% during the forecast period.

Global CRISPR Technology Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 2.80 billion
Estimated Year Value [2023]	USD 3.25 billion
Forecast Year Value [2030]	USD 9.49 billion
CAGR (%)	16.44%

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the CRISPR Technology Market.

Based on Product, market is studied across Enzymes, Guide RNA, and Kits & Reagents. The Guide RNA is projected to witness significant market share during forecast period.

Based on Services, market is studied across Cell Line Engineering, gRNA Design & Vector Construction, and Screening Services. The Cell Line Engineering is projected to witness significant market share during forecast period.

Based on Application, market is studied across Agricultural, Biomedical, and Industrial. The Agricultural is projected to witness significant market share during forecast period.

Based on End User, market is studied across Academics & Government Research Institutes, Biotechnology Companies, and Pharmaceutical Companies. The Academics & Government Research Institutes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 40.47% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the CRISPR Technology Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape CRISPR Technology Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the CRISPR Technology Market, highlighting leading vendors and their innovative profiles. These include Beam Therapeutics Inc., Caribou Biosciences, Inc., Cellectis SA, CRISPR Therapeutics AG, Editas Medicine, Inc., ERS Genomics Limited, GenScript Biotech Corporation, Hera BioLabs, Inc., Horizon Discovery Group plc, Inscripta, Inc., Intellia Therapeutics, Inc., Locanabio, Inc., Lonza Group Ltd., Mammoth Biosciences, Inc., Merck KGaA, New England Biolabs, Inc., OriGene Technologies, Inc., Precision BioSciences, Inc., Synthego Corporation, Synthorx, Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the CRISPR Technology Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the CRISPR Technology Market?

3. What is the competitive strategic window for identifying opportunities in the CRISPR Technology Market?

4. What are the latest technology trends and regulatory frameworks in the CRISPR Technology Market?

5. What is the market share of the leading vendors in the CRISPR Technology Market?

6. Which modes and strategic moves are suitable for entering the CRISPR Technology Market?

Product Code: MRR-B1685377A669

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. CRISPR Technology Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing demand for CRISPR based gene therapies
  - 5.1.1.2. Development of new vaccines and treatments of genetic diseases
  - 5.1.1.3. Growing use in biotechnological and pharmaceutical sectors
- 5.1.2. Restraints
  - 5.1.2.1. Technical challenges associated with CRISPR technology
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in sequencing Technologies
  - 5.1.3.2. Increasing government funding and investment for CRISPR technology
- 5.1.4. Challenges
  - 5.1.4.1. Complexities involved in the government regulations
5.2. Market Segmentation Analysis
- 5.2.1. Product: Increasing utilization of enzymes as core catalysts for precise gene editing
- 5.2.2. Services: Emerging preference for CRISPR-based screening services
- 5.2.3. Application: Proliferating use of CRISPR technology in the agricultural sector
- 5.2.4. End-User: Potential application of CRISPR technology in biotechnology companies
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. CRISPR Technology Market, by Product

6.1. Introduction
6.2. Enzymes
6.3. Guide RNA
6.4. Kits & Reagents

7. CRISPR Technology Market, by Services

7.1. Introduction
7.2. Cell Line Engineering
7.3. gRNA Design & Vector Construction
7.4. Screening Services

8. CRISPR Technology Market, by Application

8.1. Introduction
8.2. Agricultural
8.3. Biomedical
8.4. Industrial

9. CRISPR Technology Market, by End User

9.1. Introduction
9.2. Academics & Government Research Institutes
9.3. Biotechnology Companies
9.4. Pharmaceutical Companies

10. Americas CRISPR Technology Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific CRISPR Technology Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa CRISPR Technology Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Agreement, Collaboration, & Partnership
  - 13.3.1.1. Integrated DNA Technologies and Aldevron Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers
- 13.3.2. New Product Launch & Enhancement
  - 13.3.2.1. Revvity's (RVTY) New Launch to Widen Access to Editing Technology
  - 13.3.2.2. Vertex Teases Launch Plans for First Crispr Gene Editing Therapy Ahead of FDA Decision

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Beam Therapeutics Inc.
- 14.1.2. Caribou Biosciences, Inc.
- 14.1.3. Cellectis SA
- 14.1.4. CRISPR Therapeutics AG
- 14.1.5. Editas Medicine, Inc.
- 14.1.6. ERS Genomics Limited
- 14.1.7. GenScript Biotech Corporation
- 14.1.8. Hera BioLabs, Inc.
- 14.1.9. Horizon Discovery Group plc
- 14.1.10. Inscripta, Inc.
- 14.1.11. Intellia Therapeutics, Inc.
- 14.1.12. Locanabio, Inc.
- 14.1.13. Lonza Group Ltd.
- 14.1.14. Mammoth Biosciences, Inc.
- 14.1.15. Merck KGaA
- 14.1.16. New England Biolabs, Inc.
- 14.1.17. OriGene Technologies, Inc.
- 14.1.18. Precision BioSciences, Inc.
- 14.1.19. Synthego Corporation
- 14.1.20. Synthorx, Inc.
- 14.1.21. Takara Bio Inc.
- 14.1.22. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing